EX
EXEL.US Exelixis Inc
- Market cap
- USD 16.8B
- P/E
- 20.7x
- P/B
- 9.18x
- ROE
- 46.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EXEL.US undervalued?
Graham numberEXEL.US trades 190.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Exelixis Inc fundamental analysis
No fundamental analysis for Exelixis Inc yet.
Exelixis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibito…
Full company profileExelixis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Exelixis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 191M | 452M | 854M | 968M | 988M | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B | 2.53B |
| Gross Profit | 185M | 437M | 827M | 935M | 951M | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B | 2.44B |
| Operating Income | -28.1M | 166M | 439M | 369M | 110M | 287M | 201M | 171M | 605M | 872M | 1.02B |
| EBITDA | -22.3M | 167M | 452M | 378M | 119M | 300M | 222M | 283M | 719M | 922M | 1.11B |
| Net Income | -70.2M | 154M | 690M | 321M | 112M | 231M | 182M | 208M | 521M | 783M | 854M |
| EPS | -0.28 | 0.49 | 2.21 | 1.02 | 0.35 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | 3.34 |
| Balance Sheet | |||||||||||
| Total Assets | 598M | 655M | 1.42B | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B | 2.84B | 2.51B |
| Total Liabilities | 508M | 370M | 135M | 200M | 258M | 406M | 583M | 678M | 703M | 683M | 680M |
| Shareholders' Equity | 89.3M | 285M | 1.29B | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B | 1.83B |
| Cash & Short-term Investments | 420M | 388M | 693M | 852M | 1.21B | 1.47B | 1.31B | 995M | 1.11B | 1.06B | 892M |
| Total Debt | 189M | 72.0M | 56.9M | 50.7M | 49.1M | 51.3M | 190M | 190M | 191M | 173M | 162M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 206M | 166M | 416M | 527M | 209M | 401M | 363M | 333M | 700M | 884M | 1.12B |
| Capital Expenditure | 1.70M | 21.1M | 33.3M | 12.8M | 30.3M | 64.2M | 138M | 163M | 66.2M | 39.9M | 18.5M |
| Free Cash Flow | 205M | 144M | 382M | 514M | 179M | 337M | 224M | 170M | 634M | 844M | 1.10B |
| Ratios | |||||||||||
| ROE | -78.6% | 54.1% | 53.6% | 19.0% | 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% | 46.6% |
| ROA | -11.8% | 23.5% | 48.5% | 17.0% | 5.2% | 8.8% | 5.9% | 7.1% | 17.7% | 27.5% | 34.0% |
| Net Profit Margin | -36.7% | 34.1% | 80.8% | 33.2% | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% | 33.7% |
| Debt to Equity | 2.12x | 0.25x | 0.04x | 0.03x | 0.03x | 0.02x | 0.08x | 0.08x | 0.09x | 0.08x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Exelixis Inc dividends
Exelixis Inc has not paid dividends in the last 9 fiscal years.
Who owns Exelixis Inc
- Insiders 2.45%
- Institutions 97.55%
- Public & others 0.00%
- Shares outstanding 244M
- Free float 210M
Top funds holding EXEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 8.91M | 3.65% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 7.48M | 3.07% | -1.51% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 7.04M | 2.89% | -0.69% | Jun 2026 |
| Vanguard Small Cap Index | 5.30M | 2.17% | -3.56% | Sep 2026 |
| Invesco S&P MidCap Quality ETF | 3.11M | 1.28% | +0.15% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.95M | 1.21% | -6.54% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.72M | 1.11% | +2.68% | Oct 2026 |
| iShares Biotechnology ETF | 1.87M | 0.77% | -0.31% | Oct 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 1.83M | 0.75% | -0.33% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 1.64M | 0.67% | 0.00% | Oct 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 1.49M | 0.61% | -0.26% | Oct 2026 |
| Vanguard Explorer Inv | 1.47M | 0.60% | -6.51% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 1.35M | 0.55% | +0.05% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 1.33M | 0.54% | -2.02% | Sep 2026 |
| Avantis US Large Cap Value ETF | 1.19M | 0.49% | +0.05% | Oct 2026 |
| Fidelity Extended Market Index | 1.13M | 0.47% | -7.22% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.12M | 0.46% | +1.02% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 1.05M | 0.43% | -0.06% | Oct 2026 |
| FullerThaler Behvrll Uncnstd Eq R6 | 979K | 0.40% | -3.22% | Sep 2026 |
| Vanguard Strategic Equity Inv | 956K | 0.39% | +35.89% | Sep 2026 |
Top institutions holding EXEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 29.1M | 11.92% | -5.65% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 13.5M | 5.52% | +2.72% | Jun 2026 |
| Renaissance Technologies Corp | 13.4M | 5.50% | -2.18% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 12.0M | 4.94% | -0.35% | Jun 2026 |
| AQR Capital Management LLC | 11.0M | 4.52% | -15.82% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.0M | 4.49% | -2.74% | Jun 2026 |
| State Street Corp | 9.97M | 4.09% | -3.19% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 8.93M | 3.66% | +4.53% | Jun 2026 |
| LSV Asset Management | 8.15M | 3.34% | +5.17% | Jun 2026 |
| Geode Capital Management, LLC | 7.65M | 3.14% | -1.86% | Jun 2026 |
| D. E. Shaw & Co LP | 5.55M | 2.28% | +54.08% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.52M | 1.85% | +8.17% | Jun 2026 |
| Amvescap Plc. | 4.50M | 1.84% | +4.20% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 4.37M | 1.79% | -9.69% | Jun 2026 |
| Two Sigma Investments LLC | 4.21M | 1.73% | +90.82% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.84M | 1.57% | -13.21% | Sep 2026 |
| Genworth Financial Wealth Mgmt Inc | 3.43M | 1.41% | +1.33% | Jun 2026 |
| Nuveen, LLC | 3.28M | 1.34% | -13.37% | Jun 2026 |
| UBS Group AG | 3.17M | 1.30% | +32.35% | Jun 2026 |
| Stephens Inv Mgmt Group LLC | 2.71M | 1.11% | +7.35% | Jun 2026 |
Exelixis Inc company profile
- Company name
- Exelixis Inc
- Ticker
- EXEL.US
- Exchange
- USA Stocks
- Listed since
- Apr 7, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,077
- Fiscal year end
- December
- Address
- 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
- Phone
- 650 837 7000
- Website
- exelixis.com
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Exelixis Inc management
10- Dr. Stelios Papadopoulos Ph.D.Co-Founder & Independent Chair of the Board · born 1948
- Dr. Michael M. Morrissey Ph.D.CEO, President & Director · born 1961
- Mr. Christopher J. SennerExecutive VP & CFO · born 1968
- Dr. Brenda J. Hefti J.D., Ph.D.Senior VP & General Counsel · born 1974
- Dr. Dana T. Aftab Ph.D.Executive Vice President of Research & Development · born 1964
- Mr. Patrick Joseph Haley M.B.A.Executive Vice President of Commercial · born 1976
- Dr. William Berg M.D.Senior Vice President of Medical Affairs
- Dr. Stefan Krauss Ph.D.VP & Head of Business Development
- Mr. Andrew Ross PetersSenior Vice President of Strategy
- Ms. Deborah Burke CPASenior VP of Finance & Controller · born 1956